April 28, 2017
Recommended Topic Related To:


"The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.



Cerubidine Patient Information including How Should I Take

What should I discuss with my healthcare provider before using daunorubicin (Cerubidine)?

Do not use daunorubicin without first talking to your doctor if you have

  • kidney disease;
  • liver disease;
  • heart disease;
  • poor bone marrow function;
  • received radiation therapy that encompassed the heart; or
  • previously received treatment with doxorubicin (Adriamycin, Rubex), doxorubicin liposomal (Doxil), daunorubicin (Cerubidine), daunorubicin liposomal (DaunoXome), idarubicin (Idamycin), or mitoxantrone (Novantrone).

The use of daunorubicin may be dangerous if you have any of the conditions listed above.

Daunorubicin is in the FDA pregnancy category D. This means that daunorubicin is known to be harmful to an unborn baby. Do not use daunorubicin without first talking to your doctor if you are pregnant. Discuss with your doctor the appropriate use of birth control during treatment with daunorubicin if necessary.

Daunorubicin passes into breast milk and may harm a nursing baby. Breast-feeding should be avoided during treatment with daunorubicin.

Children have an increased risk of heart problems due to treatment with daunorubicin. Growth and gonadal development may also be affected.

How should I use daunorubicin (Cerubidine)?

Daunorubicin should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.

Your doctor will determine the correct amount and frequency of treatment with daunorubicin depending upon the type of cancer being treated and other factors. Talk to your doctor if you have any questions or concerns regarding the treatment schedule.

Your doctor will probably want you to have regularly scheduled blood tests and other medical evaluations during treatment with daunorubicin to monitor progress and side effects.

Skin accidentally exposed to daunorubicin should be rinsed thoroughly with soap and warm water.

Your healthcare provider will store daunorubicin as directed by the manufacturer. If you are storing daunorubicin at home, follow the directions provided by your healthcare provider.

Side Effects Centers

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.